Deleted in Colorectal Cancer

Merck KGaA, Darmstadt, Germany Aims to Double R&D Productivity in Oncology, Neurology and Immunology to Deliver More Medicines to Patients Faster

Retrieved on: 
Monday, November 21, 2022
Biotechnology, Pharmaceutical, Health, Oncology, ADP, Brain, BID, ATM, Neck, Merck Serono, Cancer, Biomarker, Apoptosis, Entrepreneurship, Bar Zohar, BTK, Risk, Merck Group, Health, Deleted in Colorectal Cancer, Drug development, Immunology, DNA, Phase, Science, Health care, Research, HIV disease progression rates, Inflammation, Development, Biology, Multiple sclerosis, RMS, IAP, DNA repair, Weakness, PARP1, Merck, Macrophage, MS, Electronics, Neurology, Colorectal cancer, ADC, Ataxia–telangiectasia, LA, Merck Millipore, ATR, CNS, Standard of care, Intelligence, Cisplatin, DDR, Head, Patient, Polymyositis, Fine chemical, Pharmaceutical industry, Vaccine, Debiopharm, Oncology, SCCHN

Xevinapant, which was in-licensed from Debiopharm in March 2021, builds on the companys long heritage and extensive expertise in SCCHN.

Key Points: 
  • Xevinapant, which was in-licensed from Debiopharm in March 2021, builds on the companys long heritage and extensive expertise in SCCHN.
  • M1774 has broad potential in combination with other DDR inhibitors and other medicines, and as monotherapy in the right genomic context.
  • Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics.
  • Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the companys technological and scientific advances.

Merck Aims to Double R&D Productivity in Oncology, Neurology and Immunology to Deliver More Medicines to Patients Faster

Retrieved on: 
Monday, November 21, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ADP, Brain, BID, ATM, Neck, Merck Serono, Cancer, Biomarker, Apoptosis, Entrepreneurship, Bar Zohar, BTK, Risk, Health, Deleted in Colorectal Cancer, Drug development, Immunology, DNA, Phase, Science, Health care, Research, HIV disease progression rates, Inflammation, Development, Biology, Multiple sclerosis, RMS, IAP, DNA repair, Weakness, PARP1, Conjugation, Macrophage, MS, Electronics, Neurology, Colorectal cancer, ADC, Ataxia–telangiectasia, LA, Merck Millipore, ATR, CNS, Standard of care, Intelligence, Cisplatin, DDR, Head, Patient, Polymyositis, Fine chemical, Pharmaceutical industry, Vaccine, Debiopharm, Merck, Oncology, SCCHN

Merck, a leading science and technology company, today shared updates on the companys healthcare research and development strategy, aimed at doubling R&D productivity.

Key Points: 
  • Merck, a leading science and technology company, today shared updates on the companys healthcare research and development strategy, aimed at doubling R&D productivity.
  • Xevinapant, which was in-licensed from Debiopharm in March 2021, builds on the companys long heritage and extensive expertise in SCCHN.
  • M1774 has broad potential in combination with other DDR inhibitors and other medicines, and as monotherapy in the right genomic context.
  • Building on expertise in neurology, the company is initiating a proof-of-concept study in neuromuscular conditions dermatomyositis and polymyositis with enpatoran in 2023.

Pushing past pancreatic tumors' defenses

Retrieved on: 
Wednesday, February 16, 2022
National academy, Patient, Technology, Cancer, TGM2, Laboratory, Science, SPRING, Education, University of Science and Technology of China, KRT19, Immune system, Pancreatic cancer, Breast, Pancreatic tumor, Cold Spring Harbor Laboratory, CXCL12, Student, Neoplasm, Nobel Prize, Protein, Neuroscience, Deleted in Colorectal Cancer, Research, Multimedia, Wang, University, Biomedical Research, Trial of the century, Vaccine, Pharmaceutical industry

Cancer cells weave a deactivating signal into a protective coat of armor that excludes T cells that would otherwise kill them.

Key Points: 
  • Cancer cells weave a deactivating signal into a protective coat of armor that excludes T cells that would otherwise kill them.
  • This immune deactivation pathway offers a promising new therapeutic approach for pancreatic, breast, and colorectal cancers.
  • The scientists used genetic editing to turn off the production of KRT19 or TGM2 in mouse pancreatic tumors.
  • In a previous small clinical study of pancreatic cancer patients, Fearon and collaborators showed that the drug plerixafor (a CXCL12 receptor blocker) increased the infiltration of T cells into patients' pancreatic tumor tissues.

Qurient Announces U.S. FDA Clearance of IND Application for Q901, a Novel Cancer Therapy

Retrieved on: 
Tuesday, February 8, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Max Planck Society, Trial of the century, Industry, Deleted in Colorectal Cancer, Technology transfer, Discovery Center of Springfield, CSO, Max Planck Institute of Neurobiology, Novo Nordisk, Index (publishing), Research, Apeiron, Cancer, IND, Breast, Multiple myeloma, CDK7, Program, FDA, Patient, Boehringer Ingelheim, Max Planck, Merck Group, Cell cycle, CEO, Animal, Daiichi Sankyo, BMBF, AstraZeneca, KRX, MI, Therapy, Invention, Organic, Atopic dermatitis, Prostate, Antibody, Korea Exchange, CDK, Regulation of tobacco by the U.S. Food and Drug Administration, List of Nobel laureates, Food, Partnership, Tuberculosis, LDC, Pharmaceutical industry, Management, Bayer, Qurient, LDC, Max Planck Innovation, QURIENT, LDC, MAX PLANCK INNOVATION

IND clearance for Q901 is an important step forward in developing this novel drug candidate that may provide a new alternative treatment to patients with relapsed or refractory malignancies, says Kiyean Nam, Ph.D., CEO of Qurient.

Key Points: 
  • IND clearance for Q901 is an important step forward in developing this novel drug candidate that may provide a new alternative treatment to patients with relapsed or refractory malignancies, says Kiyean Nam, Ph.D., CEO of Qurient.
  • Additional data from preclinical studies has demonstrated that selective inhibition of CDK7 specifically kills cancer cells with aberrant cell division cycle or transcriptional regulation.
  • Qurient licensed the CDK7 inhibitor program at lead stage from Lead Discovery Center (LDC) and the Max-Planck Society and further optimized the program, completed the IND-enabling studies, and submitted the IND application.
  • Qurient mainly focuses on development of novel therapeutics from discovery to human proof of concept stages through virtual R&D project management platform.

Privo Technologies, Inc. Announces Positive Results From Phase 1/2 Clinical Trial for PRV111 in Head and Neck Squamous Cell Carcinoma

Retrieved on: 
Friday, October 22, 2021
Safety, Șaeș, Compliance, Recurrence, Blood, Skin cancer, Cancer, Tongue, Neoplasm, PRV, Patient, Deleted in Colorectal Cancer, FDA, Squamous cell carcinoma, SCC, Risk, Cisplatin, Lymph, PK, Skin, Company, Clinical trial, HNSCC, Lip, NDA, Needle, Infrared spectroscopy correlation table, Toxicity, GLOBE, Incidence, Treatment, Pharmaceutical industry, Dentistry

PRV111 showed a favorable safety profile with no severe adverse events (SAEs).

Key Points: 
  • PRV111 showed a favorable safety profile with no severe adverse events (SAEs).
  • Reported treatment emergent adverse events (TEAEs) were mild or moderate in severity, and no dose-limiting toxicities (DLTs) were observed.
  • The clinical trial design was Open-Label, Single-Arm Safety, Tolerability, Anti-Tumor Effects, Systemic Exposure, and Device Technical Effects of PRV111 in subjects with Head and Neck Squamous Cell Carcinoma.
  • Squamous cell carcinoma (SCC) is cancer of the squamous cells - thin and flat cells that line the epithelia.